OpenAlex
PricingAboutJobs
Log inGet started
Work

A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.

HTML

Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2014.32.15_suppl.9051
Authors: Dejan Juric, Jean-Charles Soria, Sunil Sharma, Udai Banerji, Analia Azaro, Jayesh Desai, Francois Philippe Ringeisen, Audrey Kaag, Rajkumar Radhakrishnan, Florence Hourcade-Potelleret, Heiko Maacke, Jordi Rodon Ahnert
Institutions: Harvard University, Massachusetts General Hospital, University of Utah, Huntsman Cancer Institute, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Vall d'Hebron Hospital Universitari, The Royal Melbourne Hospital, Novartis (Switzerland), Novartis (India)
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: alpelisib, binimetinib, MEK162, PI3Kα inhibitor, advanced solid tumors, maximum tolerated dose, dose-limiting toxicity, ovarian cancer, KRAS mutation, combination therapy, dose escalation, diarrhea, hyperglycemia
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2604107344
Cites:
Cited by: 57
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security